Answers are grounded in this paper and cite their sources.
7044 Background: In BCP-ALL, blinatumomab has demonstrated efficacy in two phase 2 trials: MT 103 -203 (Gökbuget et al, Blood 2017) in minimal residual disease (MRD) and MT 102 – 211 in relapsed/refractory (R/R) disease (Topp et al Lancet Oncology 2104). We describe the long-term outcomes after blinatumomab followed by HSCT. Methods: Survival after blinatumomab and HSCT in continuous complete remission (CCR) was evaluated. In the MRD trial, 116 patients between Nov 2010 and Feb 2014 were treated with blinatumomab; in the R/R trial, 189 patients between Jan 2012 and Oct 2013 were treated. Follow up in both trials continued through 2017. Results: Most patients with HSCT in CCR in the MRD trial were >35 yrs of age whereas those in the R/R trial were younger (Table). After follow up of at least 3 yrs in the MRD trial of patients ≤35 yrs, 16/26 (62%) were alive with HSCT vs 2/9 (22%) for non-HSCT; in patients >35 yrs, 19/48 (40%) and 13/27 (48%) were alive with HSCT and for non-HSCT, respectively. Median overall survival (OS) from HSCT was not reached in patients ≤35 yrs in either trial (Table). Conclusions: These results suggest that in transplant-eligible patients in CCR, HSCT following blinatumomab is a potential option. Clinical trial information: NCT01466179, NCT01207388.Patients with on-study HSCT in CCR. MT 103 -203 N=74b n (%) MT 103 -211 N=34 n (%) Characteristics Age, n (%), yrs ≤35 26 (35) 19 (56) >35 to 55 29 (39) 9 (26) >55 19 (26) 6 (18) Median (range) 43 (18, 67) 31 (18, 65) Donor Related, n (%) 19 (26)a 8 (23) Unrelated, n (%) 53 (72) 23 (68) Matched, n (%) 20 (27) 9 (26) Unmatched 23 (31) 10 (29) Unknown, n (%) 6 (8) 3 (9) Cord 4 (5) 1 (3) Unknown, n (%) 2 (3) 3 (9) Conditioning regimen Myeloablative 32 (43) 15 (44) Reduced intensity/nonmyeloablative 35 (47) 12 (35) Unknown 7 (20) 7 (21) 100-day mortality after HST, n (%)c 5 (7) 4 (12) Outcomes Median OS from HSCT, months Age ≤35 yrs NE NE Age >35 yrs 25.7 15.9 Median RFS from HSCT, months Age ≤35 yrs NE 16.4 Age >35 yrs 15.5 15.9 NE, not estimable. a 1 haploidentical. b 74 patients received on-study HSCT in CR; Ph+ and patients not in CR at treatment start excluded. c No VOD-related deaths. Study Sponsored by Amgen.
No takes yet. Share an insight, caveat, or question.
Topp et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: